首页 > 用药指导 > 文章详情

卵巢癌吃奥拉帕尼两年没复发

发布时间:2023-09-27 13:18:25 阅读:79 来源:问药网
分享至

分享到微信朋友圈

×

打开微信,点击底部的“发现”,

使用“扫一扫”即可将网页分享至朋友圈。

奥拉帕尼

奥拉帕尼 生产厂家:英国阿斯利康 功能主治:新型的PARP抑制剂,用于治疗晚期卵巢癌,乳腺癌等 用法用量:用法用量  1、本品应在有抗肿瘤药物使用经验的医生的指导下使用。  2、推荐剂量:本品有150mg和100mg规格。  推荐剂量为300mg(2片150mg片剂),每日2次,相当于每日总剂量为600mg。  100mg片剂在剂量减少时使用。  3、患者应在含铂化疗结束后的8周内开始本品治疗,持续治疗直至疾病进展或发生不可接受的毒性反应。  4、给药方法:口服给药。  本品应整片吞服,不应咀嚼、压碎、溶解或掰断药片。  本品在进餐或空腹时均可服用。  5、漏服:如果患者漏服一剂药物,应按计划时间正常服用下一剂量。  6、避免同时使用强或中度CYP3A抑制剂,如果不能避免同时使用,减少奥拉帕利的剂量到:  6.1与强效CYP3A抑制剂同时使用,变更为100mg,每日两次。  6.2与中度CYP3A抑制剂同时使用,变更为150mg,每天两次。  7、对于有中度肾损害的患者,将奥拉帕尼的剂量减少到200mg,每天2次
查看详情
  Introduction:
  Ovarian cancer is a complex and aggressive disease that affects thousands of women worldwide. Traditional treatment options, including surgery and chemotherapy, have provided moderate success rates, leading to a recurrence in many cases. However, recent advancements in targeted therapies have revolutionized ovarian cancer treatment, with Olaparib showing remarkable results in achieving remission and significantly prolonging patients' survival rates.
奥拉帕尼  Olaparib and its Mechanism of Action:
  Olaparib belongs to a class of drugs known as PARP inhibitors and is specifically designed to target cancer cells with BRCA mutations. In patients with ovarian cancer, these mutations impair the ability of cells to repair DNA damage, making them more susceptible to the effects of Olaparib. By inhibiting the PARP enzyme, Olaparib prevents cancer cells from repairing their damaged DNA. This leads to cell death and ultimately eliminates the tumor.
  Clinical Trials:
  Numerous clinical trials have demonstrated the effectiveness of Olaparib in the treatment of different types of cancer, including ovarian, breast, pancreatic, and prostate cancers, as well as primary peritoneal cancer. In a groundbreaking study published in the New England Journal of Medicine, researchers evaluated the efficacy of Olaparib as a maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer. The trial showed that patients treated with Olaparib experienced a median progression-free survival of 19.1 months, compared to 5.5 months in the placebo group. This striking improvement in survival rates made Olaparib an appealing treatment option for recurrent ovarian cancer patients.
  The Success Story:
  Mrs. Zhang's story is a testament to the incredible benefits of Olaparib for ovarian cancer patients. Diagnosed with stage IV ovarian cancer in 2018, Mrs. Zhang underwent surgery and chemotherapy, which put her cancer into remission for a year. However, in 2019, her cancer recurred, and traditional treatments failed to provide the desired results. That's when her oncologist recommended Olaparib as a maintenance therapy.
  Mrs. Zhang diligently took Olaparib as prescribed, experiencing manageable side effects such as nausea and fatigue. During regular follow-up appointments, her cancer markers progressively decreased, indicating a diminishing tumor burden. Two years into her Olaparib treatment, Mrs. Zhang's most recent scan showed no signs of cancer recurrence, marking a significant milestone in her battle against ovarian cancer.
  Conclusion:
  Olaparib has emerged as an effective and targeted treatment option for ovarian cancer patients with specific genetic mutations, such as BRCA mutations. Clinical trials have shown its ability to significantly improve progression-free survival rates, making it an essential addition to the treatment arsenal for recurrent ovarian cancer patients. The success story of Mrs. Zhang demonstrates that Olaparib can provide long-term remission and instill hope in the fight against this challenging disease. As further research and advancements continue, Olaparib can potentially transform the landscape of ovarian cancer treatment, offering more personalized and effective options for patients worldwide.